ATE403157T1 - Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung - Google Patents
Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastungInfo
- Publication number
- ATE403157T1 ATE403157T1 AT05005356T AT05005356T ATE403157T1 AT E403157 T1 ATE403157 T1 AT E403157T1 AT 05005356 T AT05005356 T AT 05005356T AT 05005356 T AT05005356 T AT 05005356T AT E403157 T1 ATE403157 T1 AT E403157T1
- Authority
- AT
- Austria
- Prior art keywords
- art
- anp
- bnp
- hazards
- determining
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04006080 | 2004-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE403157T1 true ATE403157T1 (de) | 2008-08-15 |
Family
ID=35005597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05005356T ATE403157T1 (de) | 2004-03-15 | 2005-03-11 | Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung |
Country Status (7)
Country | Link |
---|---|
US (2) | US20050239138A1 (de) |
EP (1) | EP1577673B1 (de) |
JP (2) | JP4343866B2 (de) |
AT (1) | ATE403157T1 (de) |
CA (1) | CA2500886C (de) |
DE (1) | DE602005008497D1 (de) |
ES (1) | ES2311895T3 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7432107B2 (en) | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
EP1691200A1 (de) * | 2005-02-14 | 2006-08-16 | F. Hoffmann-La Roche Ag | Verwendung des BNP-Art und ANP-Art Peptiden für das Festsetzen der Gefahren von Herzgefäß- Komplikationen als Folge der Volumenüberlastung |
EP1986012B1 (de) | 2005-01-24 | 2012-06-06 | F. Hoffmann-La Roche AG | Verwendung von Bnp-typ für die Ermittlung von Herzversagen Risiken als Folge der Volumenüberlastung |
JP4654414B2 (ja) * | 2005-12-01 | 2011-03-23 | 独立行政法人産業技術総合研究所 | 免疫化学的検出方法、及びその検出用試薬キット |
WO2007079392A2 (en) * | 2005-12-30 | 2007-07-12 | The Trustees Of Columbia University In The City Of New York | Real-time assays of neuro-humoral to assess cardiovascular stress |
EP1816477A1 (de) * | 2006-02-06 | 2007-08-08 | F. Hoffmann-la Roche AG | Verwendung von natriuretischen Peptiden und Plazentawachstumsfaktorwerten zur Risikostratifizierung von für Herzstresstests ausgewählten Personen |
MX2009000914A (es) * | 2006-08-04 | 2009-06-18 | Hannover Med Hochschule | Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento. |
DE102007010834A1 (de) * | 2007-03-03 | 2008-09-04 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten |
ES2430290T3 (es) * | 2007-03-06 | 2013-11-19 | F. Hoffmann-La Roche Ag | Utilización de péptidos de tipo PNC para predecir la necesidad de diálisis |
JP2010536790A (ja) | 2007-08-17 | 2010-12-02 | パーデュー・リサーチ・ファウンデーション | Psma結合性リガンド−リンカー結合体及び使用方法 |
JP2011501112A (ja) * | 2007-10-10 | 2011-01-06 | エフ.ホフマン−ラ ロシュ アーゲー | 心筋梗塞のモニタリング及びその治療のための手段及び方法 |
EP2103943A1 (de) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 zur Beurteilung eines kardiovaskulären Risikos hinsichtlich Verabreichung von Entzündungshemmern |
EP2133696A1 (de) | 2008-06-10 | 2009-12-16 | Eberhardt Spanuth | Sehr geringe Konzentrationen von Troponin I oder T zur Beurteilung eines kardiovaskulären Risikos hinsichtlich der Verabreichung von Entzündungshemmern |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
CA2846285C (en) | 2011-10-17 | 2019-09-24 | F. Hoffmann-La Roche Ag | Troponin and bnp based diagnosis of risk patients and cause of stroke |
CN102854321B (zh) * | 2012-07-26 | 2015-09-02 | 博奥赛斯(天津)生物科技有限公司 | N末端b型脑钠肽前体化学发光免疫定量检测试剂盒及其制备方法 |
RU2504780C1 (ru) * | 2012-09-25 | 2014-01-20 | ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ ОБРАЗОВАТЕЛЬНОЕ УЧРЕЖДЕНИЕ ВЫСШЕГО ПРОФЕССИОНАЛЬНОГО ОБРАЗОВАНИЯ "НИЖЕГОРОДСКАЯ ГОСУДАРСТВЕННАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ И СОЦИАЛЬНОГО РАЗВИТИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ГБОУ ВПО "НижГМА" МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) | Способ оценки риска развития неблагоприятных сердечно-сосудистых событий у пациентов с заболеваниями миокарда, подвергшихся операции с искусственным кровообращением |
BR112015011118B1 (pt) | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
RS65324B1 (sr) | 2013-10-18 | 2024-04-30 | Novartis Ag | Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
CN113571191A (zh) * | 2021-08-31 | 2021-10-29 | 复旦大学附属中山医院 | 免疫检查点抑制剂相关mace发生风险的预测方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US6596476B1 (en) * | 1989-12-22 | 2003-07-22 | Abbott Laboratories | Hepatitis C assay |
US6190857B1 (en) * | 1997-03-24 | 2001-02-20 | Urocor, Inc. | Diagnosis of disease state using MRNA profiles in peripheral leukocytes |
US6622036B1 (en) * | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
EP1849475A1 (de) * | 1999-06-21 | 2007-10-31 | Eli Lilly & Company | Synergistische Verwendung von Thiazolidindionen mit glucagonartigem Peptid-1 und Agonisten davon zur Behandlung von nicht insulinabhängigen Diabetes |
AT407580B (de) * | 1999-08-20 | 2001-04-25 | Biomedica Gmbh | Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay |
US6689083B1 (en) * | 2000-11-27 | 2004-02-10 | Chf Solutions, Inc. | Controller for ultrafiltration blood circuit which prevents hypotension by monitoring osmotic pressure in blood |
FI20010019A (fi) * | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen diagnostisoimiseksi |
US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
US6969472B2 (en) * | 2001-04-19 | 2005-11-29 | Lsi Logic Corporation | Method of fabricating sub-micron hemispherical and hemicylidrical structures from non-spherically shaped templates |
US7202089B2 (en) * | 2001-09-14 | 2007-04-10 | Alan Kleinfeld | Early diagnosis of stroke |
MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
US6960472B2 (en) * | 2002-11-18 | 2005-11-01 | Ottawa Heart Institute Research Corporation | Monoclonal antibodies against N-Terminus proBNP |
WO2010007041A1 (en) * | 2008-07-14 | 2010-01-21 | Roche Diagnostics Gmbh | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
-
2005
- 2005-03-11 EP EP05005356A patent/EP1577673B1/de not_active Revoked
- 2005-03-11 DE DE602005008497T patent/DE602005008497D1/de active Active
- 2005-03-11 ES ES05005356T patent/ES2311895T3/es active Active
- 2005-03-11 AT AT05005356T patent/ATE403157T1/de not_active IP Right Cessation
- 2005-03-14 CA CA2500886A patent/CA2500886C/en active Active
- 2005-03-14 US US11/079,162 patent/US20050239138A1/en not_active Abandoned
- 2005-03-15 JP JP2005072768A patent/JP4343866B2/ja active Active
-
2008
- 2008-11-28 JP JP2008303491A patent/JP4944868B2/ja active Active
-
2011
- 2011-05-31 US US13/118,938 patent/US20110229907A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP4944868B2 (ja) | 2012-06-06 |
CA2500886A1 (en) | 2005-09-15 |
EP1577673A1 (de) | 2005-09-21 |
EP1577673B1 (de) | 2008-07-30 |
US20110229907A1 (en) | 2011-09-22 |
JP2005274569A (ja) | 2005-10-06 |
JP4343866B2 (ja) | 2009-10-14 |
US20050239138A1 (en) | 2005-10-27 |
JP2009080130A (ja) | 2009-04-16 |
CA2500886C (en) | 2010-08-10 |
DE602005008497D1 (de) | 2008-09-11 |
ES2311895T3 (es) | 2009-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE403157T1 (de) | Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung | |
Reddy et al. | Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study | |
Miyatani et al. | Pulse wave velocity for assessment of arterial stiffness among people with spinal cord injury: a pilot study | |
Tomiyama et al. | Arterial stiffness and declines in individuals with normal renal function/early chronic kidney disease | |
Tomiyama et al. | Influences of age and gender on results of noninvasive brachial–ankle pulse wave velocity measurement—a survey of 12 517 subjects | |
Andersson et al. | Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study | |
Wilkinson et al. | Increased augmentation index and systolic stress in type 1 diabetes mellitus | |
Ahimastos et al. | Gender differences in large artery stiffness pre-and post puberty | |
Tatasciore et al. | Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension | |
ATE373827T1 (de) | Kombination von markern für diabetes typ 1 und 2 | |
Moran et al. | A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome | |
Arrigo et al. | Soluble CD146 is a novel marker of systemic congestion in heart failure patients: an experimental mechanistic and transcardiac clinical study | |
Kampus et al. | The relationship between inflammation and arterial stiffness in patients with essential hypertension | |
Scott et al. | Patients with type 2 diabetes have exaggerated brachial and central exercise blood pressure: relation to left ventricular relative wall thickness | |
DE602005001299D1 (de) | Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes | |
Ferreira et al. | Optimizing the evaluation of excess exercise ventilation for prognosis assessment in pulmonary arterial hypertension | |
Hasegawa et al. | Aging-induced elevation in circulating complement C1q level is associated with arterial stiffness | |
Nalcacioglu et al. | Is N-terminal pro-brain natriuretic peptide a reliable marker for body fluid status in children with chronic kidney disease? | |
Bilinska et al. | Influence of dynamic training on hemodynamic, neurohormonal responses to static exercise and on inflammatory markers in patients after coronary artery bypass grafting | |
Mandalenakis et al. | Atrial natriuretic peptide as a predictor of atrial fibrillation in a male population study. The Study of Men Born in 1913 and 1923 | |
New et al. | Free Radical–Mediated Lipid Peroxidation and Systemic Nitric Oxide Bioavailability: Implications for Postexercise Hemodynamics | |
Kurihara et al. | Excessive alcohol intake increases the risk of arterial stiffening in men with normal blood pressure | |
Tomiyama et al. | Elevated C-reactive protein: a common marker for atherosclerotic cardiovascular risk and subclinical stages of pulmonary dysfunction and osteopenia in a healthy population | |
Couppe et al. | Skin autofluorescence is associated with arterial stiffness and insulin level in endurance runners and healthy controls-Effects of aging and endurance exercise | |
O'Donnell et al. | Indexes of aortic wave reflection are not augmented in estrogen‐deficient physically active premenopausal women |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |